$56.23
0.260.46%
At Close: -
$56.23
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Halozyme Therapeutics (NASDAQ:HALO) Stock, Analyst Ratings, Price Targets, Forecasts
Halozyme Therapeutics Inc has a consensus price target of $55.36 based on the ratings of 14 analysts. The high is $71 issued by JMP Securities on May 8, 2024. The low is $42 issued by SVB Leerink on March 16, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, HC Wainwright & Co., and HC Wainwright & Co. on July 22, 2024, July 16, 2024, and June 26, 2024, respectively. With an average price target of $59.67 between Goldman Sachs, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 6.11% upside for Halozyme Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
HC Wainwright & Co.
Benchmark
Piper Sandler
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Halozyme Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | -12.86% | Goldman Sachs | Graig Suvannavejh | $44 → $49 | Maintains | Neutral | Get Alert |
| 07/16/2024 | Buy Now | 15.6% | HC Wainwright & Co. | Mitchell Kapoor | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 15.6% | HC Wainwright & Co. | Mitchell Kapoor | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | 6.7% | Benchmark | Robert Wasserman | $50 → $60 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 15.6% | HC Wainwright & Co. | Mitchell Kapoor | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | -9.3% | Piper Sandler | Joseph Catanzaro | $48 → $51 | Downgrade | Overweight → Neutral | Get Alert |
| 06/07/2024 | Buy Now | 3.15% | Wells Fargo | Mohit Bansal | $48 → $58 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 15.6% | HC Wainwright & Co. | Mitchell Kapoor | $50 → $65 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 26.27% | JMP Securities | Jason Butler | $72 → $71 | Maintains | Market Outperform | Get Alert |
| 05/08/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | -11.08% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -3.97% | TD Cowen | Brendan Smith | → $54 | Initiates | → Outperform | Get Alert |
| 02/21/2024 | Buy Now | 28.05% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/21/2024 | Buy Now | -11.08% | HC Wainwright & Co. | Mitchell Kapoor | $48 → $50 | Maintains | Buy | Get Alert |
| 01/19/2024 | Buy Now | -11.08% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/19/2024 | Buy Now | -14.64% | HC Wainwright & Co. | Mitchell Kapoor | → $48 | Reiterates | Buy → Buy | Get Alert |
| 01/18/2024 | Buy Now | 28.05% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/18/2024 | Buy Now | -28.86% | Goldman Sachs | Graig Suvannavejh | $45 → $40 | Maintains | Neutral | Get Alert |
| 01/18/2024 | Buy Now | -14.64% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $48 | Maintains | Buy | Get Alert |
| 12/26/2023 | Buy Now | 4.93% | Morgan Stanley | Vikram Purohit | $61 → $59 | Maintains | Overweight | Get Alert |
| 10/20/2023 | Buy Now | -11.08% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
| 10/19/2023 | Buy Now | 8.48% | HC Wainwright & Co. | Mitchell Kapoor | $60 → $61 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | 6.7% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 6.7% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2023 | Buy Now | 6.7% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 6.7% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $60 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 8.48% | Morgan Stanley | Vikram Purohit | $60 → $61 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | 8.48% | HC Wainwright & Co. | Mitchell Kapoor | → $61 | Initiates | → Buy | Get Alert |
| 07/24/2023 | Buy Now | -19.97% | Goldman Sachs | Graig Suvannavejh | $43 → $45 | Downgrade | Buy → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 17.38% | JMP Securities | Jason Butler | → $66 | Reiterates | → Market Outperform | Get Alert |
| 05/10/2023 | Buy Now | 6.7% | Morgan Stanley | Vikram Purohit | $64 → $60 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | -18.19% | Piper Sandler | Joseph Catanzaro | → $46 | Upgrade | Neutral → Overweight | Get Alert |
| 03/27/2023 | Buy Now | 3.15% | Berenberg | Caroline Palomeque | → $58 | Reinstates | → Buy | Get Alert |
| 03/17/2023 | Buy Now | -14.64% | Wells Fargo | Mohit Bansal | $55 → $48 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | -25.31% | SVB Leerink | David Risinger | → $42 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/16/2023 | Buy Now | -2.19% | Wells Fargo | Mohit Bansal | $65 → $55 | Maintains | Overweight | Get Alert |
| 03/06/2023 | Buy Now | 13.82% | Morgan Stanley | Vikram Purohit | $65 → $64 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -7.52% | JP Morgan | Jessica Fye | $54 → $52 | Maintains | Overweight | Get Alert |
| 02/22/2023 | Buy Now | 17.38% | JMP Securities | Jason Butler | $62 → $66 | Reiterates | → Market Outperform | Get Alert |
| 01/11/2023 | Buy Now | 8.48% | SVB Leerink | David Risinger | $62 → $61 | Maintains | Outperform | Get Alert |
| 12/21/2022 | Buy Now | 15.6% | Morgan Stanley | Vikram Purohit | $53 → $65 | Maintains | Overweight | Get Alert |
| 12/08/2022 | Buy Now | 20.93% | Benchmark | Robert Wasserman | $55 → $68 | Maintains | Buy | Get Alert |
| 11/28/2022 | Buy Now | 15.6% | Wells Fargo | Mohit Bansal | → $65 | Initiates | → Overweight | Get Alert |
| 11/22/2022 | Buy Now | -3.97% | JP Morgan | Jessica Fye | $53 → $54 | Maintains | Overweight | Get Alert |
| 11/14/2022 | Buy Now | 10.26% | SVB Leerink | David Risinger | $52 → $62 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 10.26% | JMP Securities | Jason Butler | $60 → $62 | Maintains | Market Outperform | Get Alert |
| 09/09/2022 | Buy Now | -11.08% | Morgan Stanley | Andrew Galler | → $50 | Initiates | → Overweight | Get Alert |
| 05/26/2022 | Buy Now | 6.7% | Goldman Sachs | Graig Suvannavejh | $48 → $60 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | 3.15% | JMP Securities | Jason Butler | $55 → $58 | Maintains | Market Outperform | Get Alert |
| 11/24/2021 | Buy Now | 3.15% | Wells Fargo | — | — | Maintains | Overweight | Get Alert |
| 11/03/2021 | Buy Now | -2.19% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
| 11/03/2021 | Buy Now | -14.64% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Halozyme Therapeutics (HALO) stock?
The latest price target for Halozyme Therapeutics (NASDAQ:HALO) was reported by Goldman Sachs on July 22, 2024. The analyst firm set a price target for $49.00 expecting HALO to fall to within 12 months (a possible -12.86% downside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Halozyme Therapeutics (HALO)?
The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Goldman Sachs, and Halozyme Therapeutics maintained their neutral rating.
When was the last upgrade for Halozyme Therapeutics (HALO)?
The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.
When was the last downgrade for Halozyme Therapeutics (HALO)?
The last downgrade for Halozyme Therapeutics Inc happened on June 7, 2024 when Piper Sandler changed their price target from $48 to $51 for Halozyme Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Halozyme Therapeutics (HALO) correct?
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a maintained with a price target of $44.00 to $49.00. The current price Halozyme Therapeutics (HALO) is trading at is $56.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.